Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine
Splenic marginal zone lymphoma (SMZL) is a low-grade B cell non-Hodgkin lymphoma (NHL) characterized by the involvement of the spleen, bone marrow, and peripheral blood [1, 2]. Cytogenetically, deletion or translocation of 7q32 is reported in 40% of patients, complete or partial trisomy of 3q in 30–80% and gain of 12q in 15–20% [3, 4, 5]. While a t(8;14) IGH/MYC may occur in the setting of transformation to a high-grade NHL , these alterations are extremely rare at diagnosis . Also, a prolymphocytic evolution has been rarely recognized and it has been associated with a poor outcome . We describe here a unique case of SMZL that displayed concurrently a t(8;14)(q24;q32) at diagnosis and a prolymphocytic evolution.
splenic marginal zone lymphoma
cluster of differentiation
We are grateful to the patient for the availability of the collection of the data; nurses and colleagues from the Division of Hematology at the Department of Medicine, Padua University Hospital (PUH). We thank Dr. E. Piva from the Clinical Pathology Division of the PUH for the precious collaboration in preparing the PB smears.
GrS, MN, AV, LT, GS, and FP collected clinical data, supervised the work, and wrote the paper. SV performed the radiological analysis. MP performed the histological analysis. LB and AM performed the cytogenetic analysis.
This work was made possible in part by the AIRC grant IG 18387 to FP.
Compliance with ethical standards
The consent to publication of the material was previously obtained. The principles of the Declaration of Helsinki were followed. The Padua Region Ethic Committee approved the work (n. 4089/AO17). Data are available at the Department of Medicine, Padua University Hospital, Division of Hematology, Surgical Pathology, Radiology, and at the Istituto Oncologico Veneto (IOV), Division of Cytodiagnostics.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Andersen CL, Gruszka-Westwood A, Atkinson S, Matutes E, Catovsky D, Pedersen RK, Pedersen BB, Pulczynski S, Hokland P, Jacobsen E, Koch J (2005) Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genet Cytogenet 156(2):122–128CrossRefGoogle Scholar
- 4.Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luno E, Wlodarska I, Verhoef G, Garcia-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Sole F (2010) Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-cell lymphoma group. Blood 116(9):1479–1488CrossRefGoogle Scholar
- 5.Zinzani PL (2012) The many faces of marginal zone lymphoma. Hematol Am Soc Hematol Educ Program 2012:426–432Google Scholar